Thai CV Risk Score and Primary Prevention in Impaired Fasting Plasma Glucose or Diabetes Mellitus versus Normoglycemia in Patients with Metabolic Syndrome

Duangjai Duangrithi, Ruja Wattanasermkit, Sudarat Rungwijee, Natthanicha Khunsom


Background: Impaired fasting plasma glucose (IFG) as well as diabetes mellitus (DM) may influence the presence of another metabolic syndrome (MetS) components resulting in the different risk of cardiovascular (CV) morbidity and mortality. This study aimed to determine the impact of IFG as well as DM on the 10‑year CV risk using Thai CV risk score and primary prevention in complying with CV risk score in these patients.

Methods: This cross‑sectional study was conducted at the internal medicine clinic, Pathum Thani Hospital, Thailand. The study was approved by the hospital ethics committee and written informed consent was obtained from all patients. Patients having MetS according to the criteria of the International Diabetes Federation were enrolled while those with a history of CVD were excluded. The 10‑year CV risk was assessed using the Thai CV risk score.

Results: The total of 112 patients were enrolled in the study. They were in old age and female sex was a significantly higher proportion (61.70% vs 35.50%, P = 0.013). Of these, 72.32% had IFG or DM. Proportions of patients with moderate and high CV risk score were significantly greater in IFG/DM group and only 34.48% and 79.31% of patients with moderate or high CV risk score received aspirin and statin. IFG or DM significantly elevated CV risk score (OR = 6.66, 95% CI = 2.29, 19.58).

Conclusions: IFG/DM significantly elevated CV risk score in these patients with the strongest impact. The assessment of CV risk is highly recommended for primary prevention and long‑term CVD benefit.


Cardiovascular diseases; diabetes mellitus; metabolic syndrome; risk assessment

Full Text:



International Diabetes Federation. The IDF consensus worldwide

definition of the metabolic syndrome; c2006. Available form:

http://www.idf. org/webdata/docs/IDF_Meta_def_final.pdf.

Published. [Last cited on 2018 Aug 5].

Aekplakorn W, Chongsuvivatwong V, Tatsanavivat P,

Suriyawongpaisal P. Prevalence of metabolic syndrome defined

by the International diabetes federation and National cholesterol

education program criteria among Thai adults. Asia Pac J Public

Health 2011;23:792‑800.

Morales DD, Punzalan FE, Paz‑Pacheco E, Sy RG,

Duante CA. Metabolic syndrome in the Philippine general

population: Prevalence and risk for atherosclerotic

cardiovascular disease and diabetes mellitus. Diab Vasc Dis

Res 2008;5:36‑43.

Yen YF, Hu HY, Lin IF, Lai YJ, Su VY, Pan SW, et al.

Associations of metabolic syndrome and its components with

mortality in the elderly: A cohort study of 73,547 Taiwanese

adults. Medicine 2015;94:1‑9.

Hidaka T, Hayakawa T, Kakamu T, Kumagai T, Hiruta Y, Hata J,

et al. Prevalence of metabolic syndrome and its components

among Japanese workers by clustered business category. PLoS

One 2016;11:1‑11.

World Health Organization. Definition and diagnosis of diabetes

mellitus and intermediate hyperglycemia: Report of a WHO/IDF

consultation [Internet]; c2006. Available form: http://www.who.


of%20diabetes_new.pdf. [Last cited on 2018 Jan 31].

Rosa SD, Arcidiacono B, Chiefari E, Brunetti A, Indolfi C,

Daniela P, et al. Type 2 diabetes mellitus and cardiovascular disease: Genetic and epigenetic links. Front Endocrinol

(Lausanne) 2018;9:2.

Kim M, Kim M, Huang L, Jee SH, Le JH. Genetic risk score of

common genetic variants for impaired fasting glucose and newly

diagnosed type 2 diabetes influences oxidative stress. Sci Rep


American Diabetes Association, Standards of medical care in

diabetes 2018. Diabetes Care 2018;41:S3‑157.

Pongchaiyakul C, Nguyen TV, Kosulwat V, Rojroongwasinkul N,

Charoenkiatkul S, Pongchaiyakul C, et al. Defining obesity by

body mass index in the Thai population: An epidemiologic study.

Asia Pac J Clin Nutr 2006;15:293‑9.

Sharma SK, Ghimire A, Radhakrishnan J, Thapa L, Shrestha NR,

Paudel N, et al. Prevalence of hypertension, obesity, diabetes, and

metabolic syndrome in Nepal. Int J Hypertens 2011;2011:1‑9.

Klein BE, Klein R, Lee KE. Components of the metabolic

syndrome and risk of cardiovascular disease and diabetes in

beaver dam. Diabetes care 2002;25:1790‑4.

Berezin A. Metabolic memory phenomenon in diabetes

mellitus: Achieving and perspectives. Diabetes Metab Syndr


Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA.

‑year follow‑up of intensive glucose control in type 2 diabetes.

N Engl J Med 2008;359:1577‑89.

Rachas A, Raffaitin C, Barberger‑Gateau P, Helmer C, Ritchie K,

Tzourio C, et al. Clinical usefulness of the metabolic syndrome

for the risk of coronary heart disease does not exceed the sum

of its individual components in older men and women. The

Three‑City (3C) study. Heart 2012;98:650‑5.

Kim HK, Kim CH, Kim EH, Bae SJ, Choe J, Park JY, et al.

Impaired fasting glucose and risk of cardiovascular disease in

Korean men and women: The Korean heart study. Diabetes Care


Putadechakum S, Leelahakul V, Rodjinda P, Phanachet P,

Roongpisuthipong C. Cardiovascular risk factors and 10‑year risk

for coronary heart disease in Thai adults. Int J Sci Res 2014;4:1‑7.

Peykari N, Saeedi Moghaddam S, Djalalinia S, Kasaeian A,

Sheidaei A, Mansouri A, et al. High fasting plasma glucose

mortality effect: A comparative risk assessment in 25‑64 years

old Iranian population. Int J Prev Med 2016;7:75.

Udenze IC, Amadi CE. Cardiovascular disease risk assessment

in Nigerian adults with type 2 diabetes and metabolic syndrome

using the Framingham’s risk score. Int J Non‑Commun Dis


Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J,

Sandesara P, et al. Socioeconomic status and cardiovascular

outcomes. Circulation 2018;137:2166‑78.

Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM,

Heine RJ, Horton ES, Primary prevention of cardiovascular

disease and type 2 diabetes in patients at metabolic risk: An

endocrine society clinical practice guideline. J Clin Endocrinol

Metab 2008;93:3671‑89.

Bibbins-Domingo K. Statin use for the primary prevention

of cardiovascular disease in adults, US Preventive

Services Task Force Recommendation statement. JAMA


Zhan Y, Yu J, Chen R, Gao J, Ding R, Fu Y, et al. Socioeconomic

status and metabolic syndrome in the general population of

China: A cross‑sectional study. BMC Public Health 2012;12:921.

Verma P, Srivastava RK, Jain D. Association of lifestyle risk

factors with metabolic syndrome components: A cross‑sectional

study in Eastern India. Int J Prev Med 2018;9:6.